<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380380</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2378</org_study_id>
    <nct_id>NCT00380380</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.</brief_title>
  <official_title>A Randomized, Single-blind, Placebo Controlled, Cross-over Study to Evaluate the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Please note this study is not being conducted in the United States. The purpose of this study
      is to assess the acute effects of vildagliptin, an unapproved drug, in reducing post-meal
      glucose levels by delaying gastric emptying.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effects of acute effects of vildagliptin on gastric emptying</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on steady state levels of active GLP-1 and GIP</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting and postprandial glucose levels.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucagon secretion</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucose kinetics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on gastric peristalsis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on satiety</measure>
  </secondary_outcome>
  <enrollment>18</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be able to complete a 1-week wash-out of current anti-diabetic medications

          -  Cannot take any medications which may alter gastric motility except for cardiac
             medication at a stable dose

          -  Blood glucose criteria must be met

          -  BMI &lt;40

        Exclusion Criteria:

          -  History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary
             forms of diabetes

          -  Need for insulin within 3 months or patients on thiazolidinediones

          -  Significant concommitant disease or complications of diabetes

          -  Patients with any history of gastrointestinal surgery or positive gastrointestinal
             symptons

          -  Abnormal liver function tests as defined by the protocol

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Munich, 81377, Germany</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=15810</url>
    <description>Results for CLAF237A2378 from the Novartis Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007 May;56(5):1475-80. Epub 2007 Feb 15.</citation>
    <PMID>17303799</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2006</study_first_submitted>
  <study_first_submitted_qc>September 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2006</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vildagliptin, type 2 diabetes, gastric emptying</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

